Skip to main content
PMC home page
The EMBO Journal logoLink to The EMBO Journal
. 1997 Sep 1;16(17):5162–5177. doi: 10.1093/emboj/16.17.5162

Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution.

A C Papageorgiou 1, R Shapiro 1, K R Acharya 1
PMCID: PMC1170149  PMID: 9311977

Abstract

Human placental RNase inhibitor (hRI), a leucine-rich repeat protein, binds the blood vessel-inducing protein human angiogenin (Ang) with extraordinary affinity (Ki <1 fM). Here we report a 2.0 A resolution crystal structure for the hRI-Ang complex that, together with extensive mutagenesis data from earlier studies, reveals the molecular features of this tight interaction. The hRI-Ang binding interface is large and encompasses 26 residues from hRI and 24 from Ang, recruited from multiple domains of both proteins. However, a substantial fraction of the energetically important contacts involve only a single region of each: the C-terminal segment 434-460 of hRI and the ribonucleolytic active centre of Ang, most notably the catalytic residue Lys40. Although the overall docking of Ang resembles that observed for RNase A in the crystal structure of its complex with the porcine RNase inhibitor, the vast majority of the interactions in the two complexes are distinctive, indicating that the broad specificity of the inhibitor for pancreatic RNase superfamily proteins is based largely on its capacity to recognize features unique to each of them. The implications of these findings for the development of small, hRI-based inhibitors of Ang for therapeutic use are discussed.

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acharya K. R., Shapiro R., Allen S. C., Riordan J. F., Vallee B. L. Crystal structure of human angiogenin reveals the structural basis for its functional divergence from ribonuclease. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2915–2919. doi: 10.1073/pnas.91.8.2915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beintema J. J., Hofsteenge J., Iwama M., Morita T., Ohgi K., Irie M., Sugiyama R. H., Schieven G. L., Dekker C. A., Glitz D. G. Amino acid sequence of the nonsecretory ribonuclease of human urine. Biochemistry. 1988 Jun 14;27(12):4530–4538. doi: 10.1021/bi00412a046. [DOI] [PubMed] [Google Scholar]
  3. Beintema J. J., Schüller C., Irie M., Carsana A. Molecular evolution of the ribonuclease superfamily. Prog Biophys Mol Biol. 1988;51(3):165–192. doi: 10.1016/0079-6107(88)90001-6. [DOI] [PubMed] [Google Scholar]
  4. Bicknell R., Vallee B. L. Angiogenin activates endothelial cell phospholipase C. Proc Natl Acad Sci U S A. 1988 Aug;85(16):5961–5965. doi: 10.1073/pnas.85.16.5961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bicknell R., Vallee B. L. Angiogenin stimulates endothelial cell prostacyclin secretion by activation of phospholipase A2. Proc Natl Acad Sci U S A. 1989 Mar;86(5):1573–1577. doi: 10.1073/pnas.86.5.1573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Boix E., Wu Y., Vasandani V. M., Saxena S. K., Ardelt W., Ladner J., Youle R. J. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity. J Mol Biol. 1996 Apr 19;257(5):992–1007. doi: 10.1006/jmbi.1996.0218. [DOI] [PubMed] [Google Scholar]
  7. Buckle A. M., Schreiber G., Fersht A. R. Protein-protein recognition: crystal structural analysis of a barnase-barstar complex at 2.0-A resolution. Biochemistry. 1994 Aug 2;33(30):8878–8889. doi: 10.1021/bi00196a004. [DOI] [PubMed] [Google Scholar]
  8. Chen C. Z., Shapiro R. Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A. Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1761–1766. doi: 10.1073/pnas.94.5.1761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chothia C. The nature of the accessible and buried surfaces in proteins. J Mol Biol. 1976 Jul 25;105(1):1–12. doi: 10.1016/0022-2836(76)90191-1. [DOI] [PubMed] [Google Scholar]
  10. Clackson T., Wells J. A. A hot spot of binding energy in a hormone-receptor interface. Science. 1995 Jan 20;267(5196):383–386. doi: 10.1126/science.7529940. [DOI] [PubMed] [Google Scholar]
  11. Curran T. P., Shapiro R., Riordan J. F. Alteration of the enzymatic specificity of human angiogenin by site-directed mutagenesis. Biochemistry. 1993 Mar 9;32(9):2307–2313. doi: 10.1021/bi00060a023. [DOI] [PubMed] [Google Scholar]
  12. Fett J. W., Strydom D. J., Lobb R. R., Alderman E. M., Bethune J. L., Riordan J. F., Vallee B. L. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 1985 Sep 24;24(20):5480–5486. doi: 10.1021/bi00341a030. [DOI] [PubMed] [Google Scholar]
  13. Fields B. A., Goldbaum F. A., Ysern X., Poljak R. J., Mariuzza R. A. Molecular basis of antigen mimicry by an anti-idiotope. Nature. 1995 Apr 20;374(6524):739–742. doi: 10.1038/374739a0. [DOI] [PubMed] [Google Scholar]
  14. Gleich G. J., Loegering D. A., Bell M. P., Checkel J. L., Ackerman S. J., McKean D. J. Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci U S A. 1986 May;83(10):3146–3150. doi: 10.1073/pnas.83.10.3146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Goldman E. R., Dall'Acqua W., Braden B. C., Mariuzza R. A. Analysis of binding interactions in an idiotope-antiidiotope protein-protein complex by double mutant cycles. Biochemistry. 1997 Jan 7;36(1):49–56. doi: 10.1021/bi961769k. [DOI] [PubMed] [Google Scholar]
  16. Guillet V., Lapthorn A., Hartley R. W., Mauguen Y. Recognition between a bacterial ribonuclease, barnase, and its natural inhibitor, barstar. Structure. 1993 Nov 15;1(3):165–176. doi: 10.1016/0969-2126(93)90018-c. [DOI] [PubMed] [Google Scholar]
  17. Hallahan T. W., Shapiro R., Vallee B. L. Dual site model for the organogenic activity of angiogenin. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2222–2226. doi: 10.1073/pnas.88.6.2222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hartley R. W. Directed mutagenesis and barnase-barstar recognition. Biochemistry. 1993 Jun 15;32(23):5978–5984. doi: 10.1021/bi00074a008. [DOI] [PubMed] [Google Scholar]
  19. Hofsteenge J., Kieffer B., Matthies R., Hemmings B. A., Stone S. R. Amino acid sequence of the ribonuclease inhibitor from porcine liver reveals the presence of leucine-rich repeats. Biochemistry. 1988 Nov 15;27(23):8537–8544. doi: 10.1021/bi00423a006. [DOI] [PubMed] [Google Scholar]
  20. Howlin B., Moss D. S., Harris G. W. Segmented anisotropic refinement of bovine ribonuclease A by the application of the rigid-body TLS model. Acta Crystallogr A. 1989 Dec 1;45(Pt 12):851–861. doi: 10.1107/s0108767389009177. [DOI] [PubMed] [Google Scholar]
  21. Janin J., Chothia C. The structure of protein-protein recognition sites. J Biol Chem. 1990 Sep 25;265(27):16027–16030. [PubMed] [Google Scholar]
  22. Janin J. Elusive affinities. Proteins. 1995 Jan;21(1):30–39. doi: 10.1002/prot.340210105. [DOI] [PubMed] [Google Scholar]
  23. Jeffrey P. D., Russo A. A., Polyak K., Gibbs E., Hurwitz J., Massagué J., Pavletich N. P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature. 1995 Jul 27;376(6538):313–320. doi: 10.1038/376313a0. [DOI] [PubMed] [Google Scholar]
  24. Jimi S., Ito K., Kohno K., Ono M., Kuwano M., Itagaki Y., Ishikawa H. Modulation by bovine angiogenin of tubular morphogenesis and expression of plasminogen activator in bovine endothelial cells. Biochem Biophys Res Commun. 1995 Jun 15;211(2):476–483. doi: 10.1006/bbrc.1995.1838. [DOI] [PubMed] [Google Scholar]
  25. Jones S., Thornton J. M. Principles of protein-protein interactions. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):13–20. doi: 10.1073/pnas.93.1.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Kobe B., Deisenhofer J. A structural basis of the interactions between leucine-rich repeats and protein ligands. Nature. 1995 Mar 9;374(6518):183–186. doi: 10.1038/374183a0. [DOI] [PubMed] [Google Scholar]
  27. Lawrence M. C., Colman P. M. Shape complementarity at protein/protein interfaces. J Mol Biol. 1993 Dec 20;234(4):946–950. doi: 10.1006/jmbi.1993.1648. [DOI] [PubMed] [Google Scholar]
  28. Lee F. S., Auld D. S., Vallee B. L. Tryptophan fluorescence as a probe of placental ribonuclease inhibitor binding to angiogenin. Biochemistry. 1989 Jan 10;28(1):219–224. doi: 10.1021/bi00427a030. [DOI] [PubMed] [Google Scholar]
  29. Lee F. S., Vallee B. L. Binding of placental ribonuclease inhibitor to the active site of angiogenin. Biochemistry. 1989 Apr 18;28(8):3556–3561. doi: 10.1021/bi00434a061. [DOI] [PubMed] [Google Scholar]
  30. Lee F. S., Vallee B. L. Kinetic characterization of two active mutants of placental ribonuclease inhibitor that lack internal repeats. Biochemistry. 1990 Jul 17;29(28):6633–6638. doi: 10.1021/bi00480a012. [DOI] [PubMed] [Google Scholar]
  31. Lee F. S., Vallee B. L. Structure and action of mammalian ribonuclease (angiogenin) inhibitor. Prog Nucleic Acid Res Mol Biol. 1993;44:1–30. doi: 10.1016/s0079-6603(08)60215-9. [DOI] [PubMed] [Google Scholar]
  32. Moroianu J., Riordan J. F. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1677–1681. doi: 10.1073/pnas.91.5.1677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Mosimann S. C., Newton D. L., Youle R. J., James M. N. X-ray crystallographic structure of recombinant eosinophil-derived neurotoxin at 1.83 A resolution. J Mol Biol. 1996 Jul 26;260(4):540–552. doi: 10.1006/jmbi.1996.0420. [DOI] [PubMed] [Google Scholar]
  34. Olson K. A., Fett J. W., French T. C., Key M. E., Vallee B. L. Angiogenin antagonists prevent tumor growth in vivo. Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):442–446. doi: 10.1073/pnas.92.2.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Olson K. A., French T. C., Vallee B. L., Fett J. W. A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice. Cancer Res. 1994 Sep 1;54(17):4576–4579. [PubMed] [Google Scholar]
  36. Polakowski I. J., Lewis M. K., Muthukkaruppan V. R., Erdman B., Kubai L., Auerbach R. A ribonuclease inhibitor expresses anti-angiogenic properties and leads to reduced tumor growth in mice. Am J Pathol. 1993 Aug;143(2):507–517. [PMC free article] [PubMed] [Google Scholar]
  37. Russo N., Acharya K. R., Vallee B. L., Shapiro R. A combined kinetic and modeling study of the catalytic center subsites of human angiogenin. Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):804–808. doi: 10.1073/pnas.93.2.804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Rydel T. J., Tulinsky A., Bode W., Huber R. Refined structure of the hirudin-thrombin complex. J Mol Biol. 1991 Sep 20;221(2):583–601. doi: 10.1016/0022-2836(91)80074-5. [DOI] [PubMed] [Google Scholar]
  39. Saxena S. K., Rybak S. M., Winkler G., Meade H. M., McGray P., Youle R. J., Ackerman E. J. Comparison of RNases and toxins upon injection into Xenopus oocytes. J Biol Chem. 1991 Nov 5;266(31):21208–21214. [PubMed] [Google Scholar]
  40. Schreiber G., Fersht A. R. Interaction of barnase with its polypeptide inhibitor barstar studied by protein engineering. Biochemistry. 1993 May 18;32(19):5145–5150. doi: 10.1021/bi00070a025. [DOI] [PubMed] [Google Scholar]
  41. Shapiro R., Fox E. A., Riordan J. F. Role of lysines in human angiogenin: chemical modification and site-directed mutagenesis. Biochemistry. 1989 Feb 21;28(4):1726–1732. doi: 10.1021/bi00430a045. [DOI] [PubMed] [Google Scholar]
  42. Shapiro R., Harper J. W., Fox E. A., Jansen H. W., Hein F., Uhlmann E. Expression of Met-(-1) angiogenin in Escherichia coli: conversion to the authentic less than Glu-1 protein. Anal Biochem. 1988 Dec;175(2):450–461. doi: 10.1016/0003-2697(88)90569-6. [DOI] [PubMed] [Google Scholar]
  43. Shapiro R., Riordan J. F., Vallee B. L. LRRning the RIte of springs. Nat Struct Biol. 1995 May;2(5):350–354. doi: 10.1038/nsb0595-350. [DOI] [PubMed] [Google Scholar]
  44. Shapiro R., Vallee B. L. Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin. Proc Natl Acad Sci U S A. 1987 Apr;84(8):2238–2241. doi: 10.1073/pnas.84.8.2238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Shapiro R., Vallee B. L. Identification of functional arginines in human angiogenin by site-directed mutagenesis. Biochemistry. 1992 Dec 15;31(49):12477–12485. doi: 10.1021/bi00164a026. [DOI] [PubMed] [Google Scholar]
  46. Shapiro R., Vallee B. L. Site-directed mutagenesis of histidine-13 and histidine-114 of human angiogenin. Alanine derivatives inhibit angiogenin-induced angiogenesis. Biochemistry. 1989 Sep 5;28(18):7401–7408. doi: 10.1021/bi00444a038. [DOI] [PubMed] [Google Scholar]
  47. Shapiro R., Weremowicz S., Riordan J. F., Vallee B. L. Ribonucleolytic activity of angiogenin: essential histidine, lysine, and arginine residues. Proc Natl Acad Sci U S A. 1987 Dec;84(24):8783–8787. doi: 10.1073/pnas.84.24.8783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Strydom D. J., Fett J. W., Lobb R. R., Alderman E. M., Bethune J. L., Riordan J. F., Vallee B. L. Amino acid sequence of human tumor derived angiogenin. Biochemistry. 1985 Sep 24;24(20):5486–5494. doi: 10.1021/bi00341a031. [DOI] [PubMed] [Google Scholar]
  49. de Beer T., Vliegenthart J. F., Löffler A., Hofsteenge J. The hexopyranosyl residue that is C-glycosidically linked to the side chain of tryptophan-7 in human RNase Us is alpha-mannopyranose. Biochemistry. 1995 Sep 19;34(37):11785–11789. doi: 10.1021/bi00037a016. [DOI] [PubMed] [Google Scholar]
  50. de Vos A. M., Ultsch M., Kossiakoff A. A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science. 1992 Jan 17;255(5042):306–312. doi: 10.1126/science.1549776. [DOI] [PubMed] [Google Scholar]

Articles from The EMBO Journal are provided here courtesy of Nature Publishing Group

RESOURCES